Clinicopathological characteristics of gynecological cancer associated with hypoxia-inducible factor 1α expression: A meta-analysis including 6,612 subjects

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Jin, Yue ^a   Wang, Haolu ^b,c   Ma, Xiaowei ^b   Liang, Xiaowen ^c   Liu, Xin ^c   Wang, Yu ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; HIF1A PROTEIN, HUMAN;

ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CANCER STAGING; DISEASE FREE SURVIVAL; ENDOMETRIUM CANCER; GENE EXPRESSION; HUMAN; LYMPH NODE METASTASIS; META ANALYSIS; OVARY CANCER; OVERALL SURVIVAL; RECURRENCE RISK; SENSITIVITY ANALYSIS; SURVIVAL RATE; SYSTEMATIC REVIEW; UTERINE CERVIX CANCER; FEMALE; FEMALE GENITAL TRACT TUMOR; METABOLISM; PATHOLOGY;

FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT;

EID: 84930660043     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0127229     Document Type: Article

References (75)

1. Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, et al. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer. 2003; 97(6):1573-81. Epub 2003/03/11. doi: 10.1002/cncr.11246 PMID: 12627523.
2. Sivridis E, Giatromanolaki A, Gatter KC, Harris AL, Koukourakis MI, Tumor, et al. Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer. 2002; 95(5):1055-63. doi: 10.1002/cncr.10774 PMID: 12209691.
3. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proceedings of the National Academy of Sciences of the United States of America. 1995; 92(12):5510-4. Epub 1995/06/06. PMID: 7539918; PubMed Central PMCID: PMCPmc41725.
4. Frank B, Hoffmeister M, Klopp N, Illig T, Chang-Claude J, Brenner H. Single nucleotide polymorphisms in Wnt signaling and cell death pathway genes and susceptibility to colorectal cancer. Carcinogenesis. 2010; 31(8):1381-6. Epub 2010/04/21. doi: 10.1093/carcin/bgq082 PMID: 20403915.
5. Konac E, Onen HI, Metindir J, Alp E, Biri AA, Ekmekci A. An investigation of relationships between hypoxia-inducible factor-1 alpha gene polymorphisms and ovarian, cervical and endometrial cancers. Cancer detection and prevention. 2007; 31(2):102-9. Epub 2007/04/10. doi: 10.1016/j.cdp.2007.01.001 PMID: 17418979.
6. Kim YH, Park IA, Park WY, Kim JW, Kim SC, Park NH, et al. Hypoxia-inducible factor 1alpha polymorphisms and early-stage cervical cancer. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society. 2011; 21(1):2-7. Epub 2011/02/19. doi: 10.1097/IGC.0b013e318204f6e6 PMID: 21330825.
7. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: a cancer journal for clinicians. 2014; 64 (1):9-29. Epub 2014/01/09. doi: 10.3322/caac.21208 PMID: 24399786.
8. Birner P, Schindl M, Obermair A, Plank C, Breitenecker G, Oberhuber G. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer research. 2000; 60(17):4693-6. Epub 2000/09/15. PMID: 10987269.
9. Acs G, Xu X, Chu C, Acs P, Verma A. Prognostic significance of erythropoietin expression in human endometrial carcinoma. Cancer. 2004; 100(11):2376-86. Epub 2004/05/26. doi: 10.1002/cncr.20244 PMID: 15160341.
10. Birner P, Schindl M, Obermair A, Breitenecker G, Oberhuber G. Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clinical cancer research: an official journal of the American Association for Cancer Research. 2001; 7(6):1661-8. Epub 2001/06/19. PMID: 11410504.
11. Seeber LM, Horree N, van der Groep P, van der Wall E, Verheijen RH, van Diest PJ. Necrosis related HIF-1alpha expression predicts prognosis in patients with endometrioid endometrial carcinoma. BMC cancer. 2010; 10:307. doi: 10.1186/1471-2407-10-307 PMID: 20565904; PubMed Central PMCID: PMC2909981.
12. Bachtiary B, Schindl M, Potter R, Dreier B, Knocke TH, Hainfellner JA, et al. Overexpression of hypoxia-inducible factor 1alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2003; 9(6):2234-40. PMID: 12796391.
13. Shimogai R, Kigawa J, Itamochi H, Iba T, Kanamori Y, Oishi T, et al. Expression of hypoxia-inducible factor 1alpha gene affects the outcome in patients with ovarian cancer. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society. 2008; 18(3):499-505. Epub 2008/05/15. doi: 10.1111/j.1525-1438.2007.01055.x PMID: 18476949.
14. Daponte A, Ioannou M, Mylonis I, Simos G, Minas M, Messinis IE, et al. Prognostic significance of Hypoxia-Inducible Factor 1 alpha(HIF-1 alpha) expression in serous ovarian cancer: an immunohistochemical study. BMC cancer. 2008; 8:335. Epub 2008/11/19. doi: 10.1186/1471-2407-8-335 PMID: 19014607; PubMed Central PMCID: PMCPmc2651893.
15. Yu L, Wu S, Zhou L, Song W. Correlation between bacterial L-form infection, expression of HIF-1alpha/ MMP-9 and vasculogenic mimicry in epithelial ovarian cancer. Sheng li xue bao: [Acta physiologica Sinica]. 2012; 64(6):657-65. Epub 2012/12/22. PMID: 23258329.
16. Osada R, Horiuchi A, Kikuchi N, Yoshida J, Hayashi A, Ota M, et al. Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma. Human pathology. 2007; 38(9):1310-20. Epub 2007/06/09. doi: 10.1016/j.humpath.2007.02.010 PMID: 17555795.
17. Shen Y, Zhang XY, Shi YQ, Wang Y, Guo DH. Significance of Glut-1, HIF-1 and P53 expression in ovarian cancer. Journal of Tianjin Medical University. 2013;(05):383-6,437.
18. Su M, Zhang Y, Huang H. Expression of HIF-1alpha and MMP-2 in vasculogenic mimicry of ovarian cancer. Current Advances In Obstetrics and Gynecology. 2011; 20(2):83-7. PMID: CSCD:4456215.
19. Yu J, Huang YC, Zhang LJ, Lu YB. Expression and significance of hypoxia- inducible factor-1α and glucose transporter protein- 1 in epithelial ovarian tumor. Chinese Clinical Oncology. 2009;(03):207-11.
20. Liu LX, Liu GM, Sun YH, He XP. Analysis of the Relationship between HIF-1à gene Expression and Drug Resistance of Chemotherapy in Ovarian Cancer. Progress in Modern Biomedicine. 2012; (02):276-9.
21. Chen Y, Zhang L, Liu X. The expression and clinical significance of semaphorin4D, hypoxia-inducible factor-1α and vascular endothelial growth factor in ovarian epithelial cancer. Chinese Journal of Obstetrics and Gynecology. 2011; 46(10):786-8. PMID: CSCD:4352401.
22. Fu L, Feng W, Zhao YH, Wang AH, Wang BB, Yang LX, et al. Expression and significance of hypoxia inducible factor-la in ovarian epithelial cancer Chin J Lab Diagn. 2008;(11):1373-5.
23. Guo LL, Liu ZQ, Zhang LP, Guo GL. Expression and clinical significance of human leucocyte antigen protein G and hypoxia inducible factor- lα in epithelial ovarian carcinoma. Journal of Hainan Medical University. 2010;(04):421-4,8.
24. Nakai H, Watanabe Y, Ueda H, Hoshiai H. Hypoxia inducible factor 1-alpha expression as a factor predictive of efficacy of taxane/platinum chemotherapy in advanced primary epithelial ovarian cancer. Cancer letters. 2007; 251(1):164-7. Epub 2007/01/12. doi: 10.1016/j.canlet.2006.11.017 PMID: 17215078.
25. Ji F, Wang Y, Qiu L, Li S, Zhu J, Liang Z, et al. Hypoxia inducible factor 1alpha-mediated LOX expression correlates with migration and invasion in epithelial ovarian cancer. International journal of oncology. 2013; 42(5):1578-88. doi: 10.3892/ijo.2013.1878 PMID: 23545606; PubMed Central PMCID: PMC3661201.
26. Nakayama K, Kanzak A, Hata K, Katabuchi H, Okamura H, Miyazaki K, et al. Hypoxia-inducible factor 1 alpha (HIF-1 alpha) gene expression in human ovarian carcinoma. Cancer letters. 2002; 176(2):215-23. Epub 2002/01/24. PMID: 11804750.
27. Iida T, Yasuda M, Miyazawa M, Fujita M, Osamura RY, Hirasawa T, et al. Hypoxic status in ovarian serous and mucinous tumors: relationship between histological characteristics and HIF-1alpha/GLUT-1 expression. Archives of gynecology and obstetrics. 2008; 277(6):539-46. doi: 10.1007/s00404-007-0500-8 PMID: 18026974.
28. Chen Y, Zhang L, Pan Y, Ren XB, Hao Q. Over-Expression of Semaphorin4D, Hypoxia-Inducible Factor-1 alpha and Vascular Endothelial Growth Factor Is Related to Poor Prognosis in Ovarian Epithelial Cancer. Int J Mol Sci. 2012; 13(10):13264-74. doi: 10.3390/ijms131013264 PMID: WOS:000310677800063.
29. Li GL, Wang Z, Han RF. Expression of Mitogen Activated Protein Kinase p38 and Hypoxia- inducible Factor la in Epithefial Ovarian Cancer. Clinical Medical Engineering. 2011;(04):507-9.
30. Wong C, Wellman TL, Lounsbury KM. VEGF and HIF-1alpha expression are increased in advanced stages of epithelial ovarian cancer. Gynecologic oncology. 2003; 91(3):513-7. Epub 2003/12/17. PMID: 14675669.
31. Luo J, Peng Z, Yang K, Wang H, Yang H, Dong D, et al. Relation between the expression of hypoxia inducible factor-1alpha and angiogenesis in ovarian cancer using tissue microarray. Zhonghua fu chan ke za zhi. 2005; 40(1):38-41. Epub 2005/03/19. PMID: 15774091.
32. Wang XC, Li XY, Li SQ. Expression of HIF- 1A and VEGF and Their Relationship in Ovarian Neoplasms. Chin J Misdiagn. 2008;(20):4795-7.
33. Li SY, Yang WW, Wen QT, Xu L, Meng HM, Chen M, et al. Expression and significance of HIF-1alpha and PTEN in epithelial ovarian carcinoma and their correlation. Chinese Journal of Clinical and Experimental Pathology. 2009; 25(4):361-3. PMID: CSCD:3735660.
34. Tong XG, Xu HM, Liu YP, Hou KZ. Role of Hypoxia-inducible Factor-1alpha(HIF-1alpha) and Angiogenic Factors in Peritoneal Metastases and Prognosis of Advanced Serous Ovarian Cancer. Chinese Journal of Clinical Oncology. 2008; 35(5):272-6. PMID: CSCD:3233120.
35. Miyazawa M, Yasuda M, Fujita M, Hirasawa T, Kajiwara H, Hirabayashi K, et al. Association of hypoxia-inducible factor-1 expression with histology in epithelial ovarian tumors: a quantitative analysis of HIF-1. Archives of gynecology and obstetrics. 2009; 279(6):789-96. Epub 2008/10/22. doi: 10.1007/s00404-008-0816-z PMID: 18936945.
36. Yasuda M, Miyazawa M, Fujita M, Kajiwara H, Iida T, Hirasawa T, et al. Expression of hypoxia inducible factor-1alpha (HIF-1alpha) and glucose transporter-1 (GLUT-1) in ovarian adenocarcinomas: difference in hypoxic status depending on histological character. Oncology reports. 2008; 19(1):111-6. Epub 2007/12/22. PMID: 18097583.
37. Cheng Y, Chen G, Hong L, Zhou L, Hu M, Li B, et al. How does hypoxia inducible factor-1alpha participate in enhancing the glycolysis activity in cervical cancer? Annals of diagnostic pathology. 2013; 17(3):305-11. doi: 10.1016/j.anndiagpath.2012.12.002 PMID: 23375385.
38. Kim BW, Cho H, Chung JY, Conway C, Ylaya K, Kim JH, et al. Prognostic assessment of hypoxia and metabolic markers in cervical cancer using automated digital image analysis of immunohistochemistry. Journal of translational medicine. 2013; 11:185. doi: 10.1186/1479-5876-11-185 PMID: 23927384; PubMed Central PMCID: PMC3750663.
39. Huang M, Chen Q, Xiao J, Yao T, Bian L, Liu C, et al. Overexpression of hypoxia-inducible factor- 1alpha is a predictor of poor prognosis in cervical cancer: a clinicopathologic study and a meta-analysis. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society. 2014; 24(6):1054-64. Epub 2014/07/01. doi: 10.1097/igc.0000000000000162 PMID: 24978711.
40. Dellas K, Bache M, Pigorsch SU, Taubert H, Kappler M, Holzapfel D, et al. Prognostic impact of HIF- 1alpha expression in patients with definitive radiotherapy for cervical cancer. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al]. 2008; 184(3):169-74. doi: 10.1007/s00066-008-1764-z PMID: 18330514.
41. Li N, Sun Y, Yu Q. Expression of HIF-1α and E2F6 protein in cervical carcinoma tissues. Chinese Journal of Diagnostic Pathology. 2010; 17(3):209-11.
42. Guo K-j, Xue H, Zhang Y. Expression and Significance of HIF-lα and VEGF in Progression of Cervical Cancer. Journal of China Medical University. 2008; 37(2):237-9.
43. Liu M, Sun Y, Han SP, Zhao WB, Zheng CX, WU J. Expression and Role of HIF-1α and VEGF in Carcinogenesis and Progression of Cervical Squamous Cell Carcinoma. Chinese Journal of Clinical Oncology. 2008; 35(16):925-8.
44. Zhang LJ, Zhang SL, Lu YM. The Expression of hypoxia Inducible Factor-1α and Glucose Transporter- 1 in Cervical Cancer and Their Associations with Carcinogenesis. Journal of China Medical University. 2009; 38(2):136-8.
45. Acs G, Zhang PJ, McGrath CM, Acs P, McBroom J, Mohyeldin A, et al. Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. The American journal of pathology. 2003; 162(6):1789-806. doi: 10.1016/S0002-9440(10)64314-3 PMID: 12759237; PubMed Central PMCID: PMC1868129.
46. Hutchison GJ, Valentine HR, Loncaster JA, Davidson SE, Hunter RD, Roberts SA, et al. Hypoxiainducible factor 1alpha expression as an intrinsic marker of hypoxia: correlation with tumor oxygen, pimonidazole measurements, and outcome in locally advanced carcinoma of the cervix. Clinical cancer research: an official journal of the American Association for Cancer Research. 2004; 10(24):8405-12. Epub 2004/12/30. doi: 10.1158/1078-0432.ccr-03-0135 PMID: 15623619.
47. No JH, Jo H, Kim SH, Park IA, Kang D, Han SS, et al. Expression of vascular endothelial growth factor and hypoxia inducible factor-1alpha in cervical neoplasia. Annals of the New York Academy of Sciences. 2009; 1171:105-10. doi: 10.1111/j.1749-6632.2009.04891.x PMID: 19723043.
48. Ishikawa H, Sakurai H, Hasegawa M, Mitsuhashi N, Takahashi M, Masuda N, et al. Expression of hypoxic-inducible factor 1alpha predicts metastasis-free survival after radiation therapy alone in stage IIIB cervical squamous cell carcinoma. International journal of radiation oncology, biology, physics. 2004; 60(2):513-21. doi: 10.1016/j.ijrobp.2004.03.025 PMID: 15380586.
49. Haugland HK, Vukovic V, Pintilie M, Fyles AW, Milosevic M, Hill RP, et al. Expression of hypoxiainducible factor-1alpha in cervical carcinomas: correlation with tumor oxygenation. International journal of radiation oncology, biology, physics. 2002; 53(4):854-61. PMID: 12095550.
50. Burri P, Djonov V, Aebersold DM, Lindel K, Studer U, Altermatt HJ, et al. Significant correlation of hypoxia-inducible factor-1alpha with treatment outcome in cervical cancer treated with radical radiotherapy. International journal of radiation oncology, biology, physics. 2003; 56(2):494-501. Epub 2003/05/10. PMID: 12738326.
51. Markowska J, Grabowski JP, Tomaszewska K, Kojs Z, Pudelek J, Skrzypczak M, et al. Significance of hypoxia in uterine cervical cancer. Multicentre study. European journal of gynaecological oncology. 2007; 28(5):386-8. PMID: 17966218.
52. Ozbudak IH, Karaveli S, Simsek T, Erdogan G, Pestereli E. Neoangiogenesis and expression of hypoxia-inducible factor 1alpha, vascular endothelial growth factor, and glucose transporter-1 in endometrioid type endometrium adenocarcinomas. Gynecologic oncology. 2008; 108(3):603-8. doi: 10.1016/j. ygyno.2007.11.028 PMID: 18191183.
53. Feng Z, Gan H, Cai Z, Li N, Yang Z, Lu G, et al. Aberrant expression of hypoxia-inducible factor 1alpha, TWIST and E-cadherin is associated with aggressive tumor phenotypes in endometrioid endometrial carcinoma. Japanese journal of clinical oncology. 2013; 43(4):396-403. doi: 10.1093/jjco/hys237 PMID: 23372184.
54. Espinosa I, Jose Carnicer M, Catasus L, Canet B, D'Angelo E, Zannoni GF, et al. Myometrial invasion and lymph node metastasis in endometrioid carcinomas: tumor-associated macrophages, microvessel density, and HIF1A have a crucial role. The American journal of surgical pathology. 2010; 34(11):1708-14. Epub 2010/10/22. doi: 10.1097/PAS.0b013e3181f32168 PMID: 20962622.
55. Pijnenborg JM, Wijnakker M, Hagelstein J, Delvoux B, Groothuis PG. Hypoxia contributes to development of recurrent endometrial carcinoma. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society. 2007; 17(4):897-904. doi: 10.1111/j.1525-1438.2007.00893.x PMID: 17359291.
56. Pansare V, Munkarah AR, Schimp V, Haitham Arabi M, Saed GM, Morris RT, et al. Increased expression of hypoxia-inducible factor 1alpha in type I and type II endometrial carcinomas. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 2007; 20(1):35-43. doi: 10.1038/modpathol.3800718 PMID: 17099695.
57. Horree N, van Diest PJ, van der Groep P, Sie-Go DM, Heintz AP. Hypoxia and angiogenesis in endometrioid endometrial carcinogenesis. Cellular oncology: the official journal of the International Society for Cellular Oncology. 2007; 29(3):219-27. Epub 2007/04/25. PMID: 17452774.
58. Koda M, Sulkowska M, Wincewicz A, Kanczuga-Koda L, Musiatowicz B, Szymanska M, et al. Expression of leptin, leptin receptor, and hypoxia-inducible factor 1 alpha in human endometrial cancer. Annals of the New York Academy of Sciences. 2007; 1095:90-8. doi: 10.1196/annals.1397.013 PMID: 17404022.
59. Aybatli A, Sayin C, Kaplan PB, Varol F, Altaner S, Sut N. The investigation of tumoral angiogenesis with HIF-1 alpha and microvessel density in women with endometrium cancer. Journal of the Turkish German Gynecological Association. 2012; 13(1):37-44. doi: 10.5152/jtgga.2012.02 PMID: 24627673; PubMed Central PMCID: PMC3940222.
60. Yeramian A, Santacana M, Sorolla A, Llobet D, Encinas M, Velasco A, et al. Nuclear factor-kappaB2/ p100 promotes endometrial carcinoma cell survival under hypoxia in a HIF-1alpha independent manner. Laboratory investigation; a journal of technical methods and pathology. 2011; 91(6):859-71. doi: 10.1038/labinvest.2011.58 PMID: 21537326.
61. Li XL, Zhong XJ, Deng YL. P38MAPK regulation of HIF-1 alpha on the growth of endometrial carcinoma metastasis impact. China Journal of Modern Medicine. 2008; 18(19):2802-4.
62. Zhai L, Liu YD, Dai M. Relationship between expressions of PTEN and HIF-1α in adenoendometrial carcinoma. Journal of Harbin Medical University. 2007; 41(3):247-9.
63. Pan X, Yang Q, Sun Z-b. Expression of HIF-1α, MMP-2 in endometrial carcinoma and its clinical significance. Chinese Journal of Practical Gynecology and Obstetrics. 2011; 27(1):48-50.
64. Song Q, Xie YG, Shi GS, Zhang JG, Huang H, Xiao J. Correlational research between gene expression of HIF-1α,VEGF and color Doppler ultrasound appearance in endometrial cancer. Chin J Med Imaging Technol. 2009; 25(5):870-3.
65. Wang J, Liu ZC, Ma ZH, Wang M, Zhang SL. The Effect of VEGF, HIF-1α,Vasohibin in Tumor Angiogenesis of Endometrioid Adenocarcinoma and its Relation to Prognosis. Chines Journal of Histochemistry and Cytochemistry. 2010; 19(1):43-8.
66. Tanimoto K, Yoshiga K, Eguchi H, Kaneyasu M, Ukon K, Kumazaki T, et al. Hypoxia-inducible factor- 1alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance. Carcinogenesis. 2003; 24(11):1779-83. Epub 2003/08/16. doi: 10.1093/carcin/bgg132 PMID: 12919954.
67. Shieh TM, Chang KW, Tu HF, Shih YH, Ko SY, Chen YC, et al. Association between the polymorphisms in exon 12 of hypoxia-inducible factor-1alpha and the clinicopathological features of oral squamous cell carcinoma. Oral oncology. 2010; 46(9):e47-53. Epub 2010/07/27. doi: 10.1016/j. oraloncology.2010.04.009 PMID: 20656543.
68. Munoz-Guerra MF, Fernandez-Contreras ME, Moreno AL, Martin ID, Herraez B, Gamallo C. Polymorphisms in the hypoxia inducible factor 1-alpha and the impact on the prognosis of early stages of oral cancer. Annals of surgical oncology. 2009; 16(8):2351-8. Epub 2009/05/19. doi: 10.1245/s10434-009-0503-8 PMID: 19449077.
69. Seeber LM, Horree N, Vooijs MA, Heintz AP, van der Wall E, Verheijen RH, et al. The role of hypoxia inducible factor-1alpha in gynecological cancer. Critical reviews in oncology/hematology. 2011; 78 (3):173-84. Epub 2010/07/16. doi: 10.1016/j.critrevonc.2010.05.003 PMID: 20627616.
70. Lee S, Garner EI, Welch WR, Berkowitz RS, Mok SC. Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma. Gynecologic oncology. 2007; 106(2):311-7. Epub 2007/05/29. doi: 10.1016/j.ygyno.2007.03.041 PMID: 17532031; PubMed Central PMCID: PMCPmc1995602.
71. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, et al. Overexpression of hypoxiainducible factor 1alpha in common human cancers and their metastases. Cancer research. 1999; 59(22):5830-5. Epub 1999/12/03. PMID: 10582706.
72. Risinger JI, Hayes AK, Berchuck A, Barrett JC. PTEN/MMAC1 mutations in endometrial cancers. Cancer research. 1997; 57(21):4736-8. Epub 1997/11/14. PMID: 9354433.
73. Kong D, Suzuki A, Zou TT, Sakurada A, Kemp LW, Wakatsuki S, et al. PTEN1 is frequently mutated in primary endometrial carcinomas. Nature genetics. 1997; 17(2):143-4. Epub 1997/11/05. doi: 10.1038/ ng1097-143 PMID: 9326929.
74. Cohn DE, Basil JB, Venegoni AR, Mutch DG, Rader JS, Herzog TJ, et al. Absence of PTEN repeat tract mutation in endometrial cancers with microsatellite instability. Gynecologic oncology. 2000; 79(1):101-6. Epub 2000/09/28. doi: 10.1006/gyno.2000.5900 PMID: 11006040.
75. Tang X, Zhang Q, Nishitani J, Brown J, Shi S, Le AD. Overexpression of human papillomavirus type 16 oncoproteins enhances hypoxia-inducible factor 1 alpha protein accumulation and vascular endothelial growth factor expression in human cervical carcinoma cells. Clinical cancer research: an official journal of the American Association for Cancer Research. 2007; 13(9):2568-76. Epub 2007/05/03. doi: 10.1158/1078-0432.ccr-06-2704 PMID: 17473185.